kymera - Search News

News

Gilead, Kymera and breast cancer

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Reuters on MSN · 2d

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal,

Seeking Alpha on MSN · 2d

Gilead and Kymera in pact to develop cancer drugs

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to develop and sell a band of cancer drugs. Under the deal, Kymera could receive up to $750M,

PharmExec2d

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results